Development of a Sol Particle Homogeneous Immunoassay for Measuring Full-Length Selenoprotein P in Human Serum

Journal of Clinical Laboratory Analysis

Volumn 30, Issue 2, 2016, Pages 114-122

  Tanaka, Mutsumi ^a   Saito, Yoshiro ^b   Misu, Hirofumi ^c   Kato, Seiji ^a   Kita, Yuki ^c   Takeshita, Yumie ^c   Kanamori, Takehiro ^c   Nagano, Toru ^d   Nakagen, Masatoshi ^d   Urabe, Takeshi ^d   Takamura, Toshinari ^c   Kaneko, Shuichi ^c   Takahashi, Kazuhiko ^e   Matsuyama, Naoto ^a  

^a Alfresa Pharma Corporation   (Japan)

^b DOSHISHA UNIVERSITY   (Japan)

^c KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^d Public Central Hospital of Matto Ishikawa   (Japan)

^e HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Colloidal gold; Diabetes; Homogeneous immunoassay; Metformin; Selenoprotein P

Indexed keywords

BILIRUBIN; COLLOIDAL GOLD; HEMOGLOBIN; KALLIKREIN; MONOCLONAL ANTIBODY; RHEUMATOID FACTOR; SELENOPROTEIN P; ANTICOAGULANT AGENT;

AMINO TERMINAL SEQUENCE; ARTICLE; AUTOANALYZER; BLOOD ANALYSIS; BLOOD SAMPLING; CARBOXY TERMINAL SEQUENCE; CHYLE; CORRELATION COEFFICIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; LIMIT OF DETECTION; MEASUREMENT ACCURACY; MOLECULAR RECOGNITION; NORMAL HUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DOMAIN; PROTEIN PURIFICATION; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; SOL PARTICLE HOMOGENOUS IMMUNOASSAY; VOLUNTEER; WESTERN BLOTTING; BLOOD; CALIBRATION; HEMAGGLUTINATION; PROCEDURES; PROTEIN DEGRADATION;

ANTICOAGULANTS; CALIBRATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GOLD COLLOID; HEMAGGLUTINATION; HUMANS; IMMUNOASSAY; KALLIKREINS; LIMIT OF DETECTION; PROTEOLYSIS; SELENOPROTEIN P;

EID: 84961113395     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21824     Document Type: Article

References (28)

1. Burk RF, Hill KE. Selenoprotein P-expression, functions, and roles in mammals. Biochim Biophys Acta 2009;1790:1441-1447.
2. Saito Y, Takahashi K. Selenoprotein P: Its structure and functions. J Health Sci 2000;46:409-413.
3. Saito Y, Takahashi K. Characterization of selenoprotein P as a selenium supply protein. Eur J Biochem 2002;269:5746-5751.
4. Saito Y, Sato N, Hirashima M, Takebe G, Nagasawa S, Takahashi K. Domain structure of bi-functional selenoprotein P. Biochem J 2004;381:841-846.
5. Saito Y, Hayashi T, Tanaka A, et al. Selenoprotein P in human plasma as an extracellular phospholipid hydroperoxide glutathione peroxidase. Isolation and enzymatic characterization of human selenoprotein P. J Biol Chem 1999;274:2866-2871.
6. Takebe G, Yarimizu J, Saito Y, et al. A comparative study on the hydroperoxide and thiol specificity of the glutathione peroxidase family and selenoprotein P. J Biol Chem 2002;277:41254-41258.
7. Schomburg L, Schweizer U, Holtmann B, Flohé L, Sendtner M, Köhrle J. Gene disruption discloses role of selenoprotein P in selenium delivery to target tissues. Biochem J 2003;370:397-402.
8. Meyer HA, Hollenbach B, Stephan C, et al. Reduced serum selenoprotein P concentrations in German prostate cancer patients. Cancer Epidemiol Biomarkers Prev 2009;18:2386-2390.
9. Forceville X, Mostert V, Pierantoni A, et al. Selenoprotein P, rather than glutathione peroxidase, as a potential marker of septic shock and related syndromes. Eur Surg Res 2009;43:338-347.
10. Hollenbach B, Morgenthaler NG, Struck J, et al. New assay for the measurement of selenoprotein P as a sepsis biomarker from serum. J Trace Elem Med Biol 2008;22:24-32.
11. Meyer HA, Endermann T, Stephan C, et al. Selenoprotein P status correlates to cancer-specific mortality in renal cancer patients. PLoS One 2012;7:e46644.
12. Misu H, Takamura T, Takayama H, et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab 2010;12:483-495.
13. Misu H, Ishikura K, Kurita S, et al. Inverse correlation between serum levels of selenoprotein P and adiponectin in patients with type 2 diabetes. PLoS One 2012;7:e34952.
14. Yang SJ, Hwang SY, Choi HY, et al. Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: Implications for insulin resistance, inflammation, and atherosclerosis. J Clin Endocrinol Metab 2011;96:E1325-E1329.
15. Saito Y, Watanabe Y, Saito E, Honjoh T, Takahashi K. Production and application of monoclonal antibodies to human selenoprotein P. J Health Sci 2001;47:346-352.
16. Leuvering JH, Thal PJ, Van der Waart M, Schuurs AH. A sol particle agglutination assay for human chorionic gonadotrophin. J Immunol Methods 1981;45:183-194.
17. Wielaard F, Denissen A, van der Veen L, Rutjes I. A sol-particle immunoassay for determination of anti-rubella antibodies; development and clinical validation. J Virol Methods 1987;17:149-158.
18. Englebienne P, Van Hoonacker A, Valsamis J. Rapid homogeneous immunoassay for human ferritin in the Cobas Mira using colloidal gold as the reporter reagent. Clin Chem 2000;46:2000-2003.
19. Tanaka M, Matsuo K, Enomoto M, Mizuno K. A sol particle homogeneous immunoassay for measuring serum cystatin C. Clin Biochem 2004;37:27-35.
20. De Roe C, Courtoy PJ, Baudhuin P. A model of protein-colloidal gold interactions. J Histochem Cytochem 1987;35:1191-1198.
21. Clinical and Laboratory Standards Institute. Protocols for Determination of Limits of Detection and Limits of Quantitation, Approved Guideline. CLIS document EP17A. Wayne, PA, USA: CLIS; 2004.
22. Clinical and Laboratory Standards Institute. Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline. CLIS document EP6-A. Wayne, PA, USA: CLIS; 2003.
23. Clinical and Laboratory Standards Institute. Evaluation of Precision Performance of Clinical Chemistry Devices; Approved Guideline-Second Edition. CLIS document EP5-A2. Wayne, PA, USA:CLIS; 2004.
24. Jpn J Clinical Laboratory Automation. Performance test manual of the daily clinical test. Jpn J Clin Lab Autom 2002;27(Suppl. 1):27-30.
25. Speckmann B, Sies H, Steinbrenner H. Attenuation of hepatic expression and secretion of selenoprotein P by metformin. Biochem Biophys Res Commun 2009;387:158-163.
26. Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: A systematic review. Diabetologia 2006;49:434-441.
27. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
28. Diabetes Prevention Program Research Group. 10-Year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677-1686.